Urology Practice Management - October 2016, Vol 5, No 5
Healthcare reform and associated economic pressures “have changed the rules” for virtually all healthcare providers, and providers must reinvent strategic approaches and care delivery models in response to these changes, said Max Reiboldt, CPA, President and Chief Executive Officer, the Coker Group.
During her presentation at the 2016 AUA Practice Management Conference, Ms Maldonado reviewed some of the problem areas that have come to the attention of coding consultants for the AUA coding hotline.
IsoPSA, a New Biomarker Test, Differentiates High- and Low-Grade Prostate Cancer, Improves Diagnostic Accuracy
The IsoPSA assay holds promise for improved diagnostic accuracy, said Eric A. Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic, OH, at the 2016 American Urological Association annual meeting.
“A shorter, hypofractionated schedule of radiation is noninferior to conventional radiation for disease control in men with intermediate-risk prostate cancer at a median follow-up of 6 years,” said lead investigator Charles N. Catton, MD, FRCPC, Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada, who presented the study results.
The following clinical trials represent a selection of key studies that are currently recruiting patients with prostate cancer for investigations of new treatments or new combinations for patients with prostate cancer. Each clinical trial description includes the NLM Identifier used by ClinicalTrials.gov. The information below can help urologists direct their eligible patients to one of these studies.
Results 1 - 5 of 5